With a sample size of 6:After 3 months, 3 out of 6 patients...

With a sample size of 6:

After 3 months, 3 out of 6 patients experienced a partial response, a 50% overall response rate(“ORR”) according to immune related response criteria (“irRC”);• The current disease control rate for this group is 66% (4/6);

Seems disappointing.

With a sample size of 18:

ORR of 33% (6/18) was reported according to the protocol when measured from start ofcombination treatment (cycle 5 of pembrolizumab treatment) in patients with suboptimal responseto pembrolizumab monotherapy;

Again, seems disappointing